Francesco Sclafani1, Tae Y Kim1, David Cunningham2, Tae W Kim1, Josep Tabernero1, Hans J Schmoll1, Jae K Roh1, Sun Y Kim1, Young S Park1, Tormod K Guren1, Eliza Hawkes1, Steven J Clarke1, David Ferry1, Jan-Erik Frödin1, Mark Ayers1, Michael Nebozhyn1, Clare Peckitt1, Andrey Loboda1, David J Mauro1, David J Watkins1. 1. The Royal Marsden NHS Foundation Trust, London and Surrey, UK (FS, DC, EH, CP, DJW); Seoul National University College of Medicine, Seoul, Korea (TYK); Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (TWK); Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain (JT); University Clinic Halle (Saale), Martin Luther University Halle-Wittenberg, Halle, Germany (HJS); Yonsey Cancer Center, Yonsey University, College of Medicine, Seoul, Korea (JKR); Center for Colorectal Cancer, National Cancer Center, Seoul, Korea (SYK); Samsung Medical Center, Seoul, Korea (YSP); Oslo University Hospital, Oslo, Norway (TKG); Concord Repatriation General Hospital, Concord, Sydney, Australia (SJC); New Cross Hospital, Wolverhamptom, UK (DF); Karolinska University Hospital, Stockholm, Sweden (JEF); Merck & Co., Inc., Whitehouse Station, NJ (MA, MN, AL, DJM). 2. The Royal Marsden NHS Foundation Trust, London and Surrey, UK (FS, DC, EH, CP, DJW); Seoul National University College of Medicine, Seoul, Korea (TYK); Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (TWK); Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain (JT); University Clinic Halle (Saale), Martin Luther University Halle-Wittenberg, Halle, Germany (HJS); Yonsey Cancer Center, Yonsey University, College of Medicine, Seoul, Korea (JKR); Center for Colorectal Cancer, National Cancer Center, Seoul, Korea (SYK); Samsung Medical Center, Seoul, Korea (YSP); Oslo University Hospital, Oslo, Norway (TKG); Concord Repatriation General Hospital, Concord, Sydney, Australia (SJC); New Cross Hospital, Wolverhamptom, UK (DF); Karolinska University Hospital, Stockholm, Sweden (JEF); Merck & Co., Inc., Whitehouse Station, NJ (MA, MN, AL, DJM). david.cunningham@rmh.nhs.uk.
Abstract
BACKGROUND: Insulin-like growth factor type 1 receptor (IGF-1R) mediates resistance to epidermal growth factor receptor (EGFR) inhibition and may represent a therapeutic target. We conducted a multicenter, randomized, double blind, phase II/III trial of dalotuzumab, an anti-IGF-1R monoclonal antibody, with standard therapy in chemo-refractory, KRAS wild-type metastatic colorectal cancer. METHODS:Eligible patients were randomly assigned to dalotuzumab 10mg/kg weekly (arm A), dalotuzumab 7.5mg/kg every alternate week (arm B), or placebo (arm C) in combination with cetuximab and irinotecan. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included exploratory biomarker analyses. All statistical tests were two-sided. RESULTS: The trial was prematurely discontinued for futility after 344 eligible KRAS wild-type patients were included in the primary efficacy population (arm A = 116, arm B = 117, arm C = 111). Median PFS was 3.9 months in arm A (hazard ratio [HR] = 1.33, 95% confidence interval [CI] = 0.98 to 1.83, P = .07) and 5.4 months in arm B (HR = 1.13, 95% CI = 0.83 to 1.55, P = .44) compared with 5.6 months in arm C. Median OS was 10.8 months in arm A (HR = 1.41, 95% CI = 0.99 to 2.00, P = .06) and 11.6 months in arm B (HR = 1.26, 95% CI = 0.89 to 1.79, P = .18) compared with 14.0 months in arm C. Grade 3 or higher asthenia and hyperglycaemia occurred more frequently with dalotuzumab compared with placebo. In exploratory biomarker analyses, patients with high IGF-1 mRNA tumors in arm A had numerically better PFS (5.6 vs 3.6 months, HR = 0.59, 95% CI = 0.28 to 1.23, P = .16) and OS (17.9 vs 9.4 months, HR = 0.67, 95% CI = 0.31 to 1.45, P = .31) compared with those with high IGF-1 mRNA tumors in arm C. In contrast, in arm C high IGF-1 mRNA expression predicted lower response rate (17.6% vs 37.3%, P = .04), shorter PFS (3.6 vs 6.6 months, HR = 2.15, 95% CI = 1.15 to 4.02, P = .02), and shorter OS (9.4 vs 15.5 months, HR = 2.42, 95% CI = 1.21 to 4.82, P = .01). CONCLUSIONS: Adding dalotuzumab to irinotecan and cetuximab was feasible but did not improve survival outcome. IGF-1R ligands are promising biomarkers for differential response to anti-EGFR and anti-IGF-1R therapies.
RCT Entities:
BACKGROUND:Insulin-like growth factor type 1 receptor (IGF-1R) mediates resistance to epidermal growth factor receptor (EGFR) inhibition and may represent a therapeutic target. We conducted a multicenter, randomized, double blind, phase II/III trial of dalotuzumab, an anti-IGF-1R monoclonal antibody, with standard therapy in chemo-refractory, KRAS wild-type metastatic colorectal cancer. METHODS: Eligible patients were randomly assigned to dalotuzumab 10mg/kg weekly (arm A), dalotuzumab 7.5mg/kg every alternate week (arm B), or placebo (arm C) in combination with cetuximab and irinotecan. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included exploratory biomarker analyses. All statistical tests were two-sided. RESULTS: The trial was prematurely discontinued for futility after 344 eligible KRAS wild-type patients were included in the primary efficacy population (arm A = 116, arm B = 117, arm C = 111). Median PFS was 3.9 months in arm A (hazard ratio [HR] = 1.33, 95% confidence interval [CI] = 0.98 to 1.83, P = .07) and 5.4 months in arm B (HR = 1.13, 95% CI = 0.83 to 1.55, P = .44) compared with 5.6 months in arm C. Median OS was 10.8 months in arm A (HR = 1.41, 95% CI = 0.99 to 2.00, P = .06) and 11.6 months in arm B (HR = 1.26, 95% CI = 0.89 to 1.79, P = .18) compared with 14.0 months in arm C. Grade 3 or higher asthenia and hyperglycaemia occurred more frequently with dalotuzumab compared with placebo. In exploratory biomarker analyses, patients with high IGF-1 mRNA tumors in arm A had numerically better PFS (5.6 vs 3.6 months, HR = 0.59, 95% CI = 0.28 to 1.23, P = .16) and OS (17.9 vs 9.4 months, HR = 0.67, 95% CI = 0.31 to 1.45, P = .31) compared with those with high IGF-1 mRNA tumors in arm C. In contrast, in arm C high IGF-1 mRNA expression predicted lower response rate (17.6% vs 37.3%, P = .04), shorter PFS (3.6 vs 6.6 months, HR = 2.15, 95% CI = 1.15 to 4.02, P = .02), and shorter OS (9.4 vs 15.5 months, HR = 2.42, 95% CI = 1.21 to 4.82, P = .01). CONCLUSIONS: Adding dalotuzumab to irinotecan and cetuximab was feasible but did not improve survival outcome. IGF-1R ligands are promising biomarkers for differential response to anti-EGFR and anti-IGF-1R therapies.
Authors: Lecia V Sequist; Jhanelle Elaine Gray; Wael A Harb; Ariel Lopez-Chavez; Robert C Doebele; Manuel R Modiano; David Michael Jackman; Maria Quintos Baggstrom; Akin Atmaca; Enriqueta Felip; Mariano Provencio; Manuel Cobo; Bambang Adiwijaya; Geoffrey Kuesters; Walid S Kamoun; Karen Andreas; J Marc Pipas; Sergio Santillana; Byoung Chul Cho; Keunchil Park; Frances A Shepherd Journal: Oncologist Date: 2019-04-11
Authors: Marta Schirripa; Wu Zhang; Volker Heinemann; Shu Cao; Satoshi Okazaki; Dongyun Yang; Fotios Loupakis; Martin D Berger; Yan Ning; Yuji Miyamoto; Mitsukuni Suenaga; Roel F Gopez; Jordan D West; Diana Hanna; Afsaneh Barzi; Alfredo Falcone; Sebastian Stintzing; Heinz-Josef Lenz Journal: Int J Cancer Date: 2017-05-10 Impact factor: 7.396
Authors: Eric R Molina; Letitia K Chim; Sergio Barrios; Joseph A Ludwig; Antonios G Mikos Journal: Tissue Eng Part B Rev Date: 2020-02-14 Impact factor: 6.389
Authors: José Baselga; Serafin M Morales; Ahmad Awada; Joanne L Blum; Antoinette R Tan; Marianne Ewertz; Javier Cortes; Beverly Moy; Kathryn J Ruddy; Tufia Haddad; Eva M Ciruelos; Peter Vuylsteke; Scot Ebbinghaus; Ellie Im; Lamar Eaton; Kumudu Pathiraja; Christine Gause; David Mauro; Mary Beth Jones; Hope S Rugo Journal: Breast Cancer Res Treat Date: 2017-03-21 Impact factor: 4.872
Authors: Joyce F Liu; Isabelle Ray-Coquard; Frederic Selle; Andrés M Poveda; David Cibula; Hal Hirte; Felix Hilpert; Francesco Raspagliesi; Laurence Gladieff; Philipp Harter; Salvatore Siena; Josep Maria Del Campo; Isabelle Tabah-Fisch; Joseph Pearlberg; Victor Moyo; Kaveh Riahi; Rachel Nering; William Kubasek; Bambang Adiwijaya; Akos Czibere; R Wendel Naumann; Robert L Coleman; Ignace Vergote; Gavin MacBeath; Eric Pujade-Lauraine Journal: J Clin Oncol Date: 2016-10-23 Impact factor: 44.544
Authors: Eric R Molina; Letitia K Chim; Maria C Salazar; Shail M Mehta; Brian A Menegaz; Salah-Eddine Lamhamedi-Cherradi; Tejus Satish; Sana Mohiuddin; David McCall; Ana Maria Zaske; Branko Cuglievan; Alexander J Lazar; David W Scott; Jane K Grande-Allen; Joseph A Ludwig; Antonios G Mikos Journal: Acta Biomater Date: 2019-09-19 Impact factor: 8.947